Serve BioPharma Obtains Orphan Regenerative Medicine Product Designation for Primary Malignant Bone Tumor Therapeutic Drug Using Oncolytic Virus Surv.m-CRA-1
NQ Score
0/100
N1 Content Completeness
5
Key facts
- Serve BioPharma Obtains Orphan Regenerative Medicine Product Designation for Primary Malignant Bone Tumor Therapeutic Drug Using Oncolytic Virus Surv.m-CRA-1
- Serve BioPharma announced on May 8, 2026, that its therapeutic drug for primary malignant bone tumors, utilizing the proprietary oncolytic adenovirus "Surv.m-CRA-1," has been designated as an "Orphan Regenerative Medicine Product" by the Minister of Health, Labour and Welfare. This designation is expected to accelerate the development and practical application of the treatment, providing hope for patients with intractable diseases.
- Source: PR TIMES
- Date: Tue May 12 2026 04:32:40 GMT+0900 (Japan Standard Time)
Direct answer
Serve BioPharma announced on May 8, 2026, that its therapeutic drug for primary malignant bone tumors, utilizing the proprietary oncolytic adenovirus "Surv.m-CRA-1," has been designated as an "Orphan Regenerative Medicine Product" by the Minister of Health, Labour and Welfare. This designation is expected to accelerate the development and practical application of the treatment, providing hope for patients with intractable diseases.
- Citation
- Serve BioPharma Obtains Orphan Regenerative Medicine Product Designation for Primary Malignant Bone Tumor Therapeutic Drug Using Oncolytic Virus Surv.m-CRA-1 (Tue May 12 2026 04:32:40 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Tue May 12 2026 04:32:40 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Serve BioPharma announced on May 8, 2026, that its therapeutic drug for primary malignant bone tumors, utilizing the proprietary oncolytic adenovirus "Surv.m-CRA-1," has been designated as an "Orphan Regenerative Medicine Product" by the Minister of Health, Labour and Welfare. This designation is expected to accelerate the development and practical application of the treatment, providing hope for patients with intractable diseases.
AI Analysis
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: Serve BioPharma announced on May 8, 2026, that its therapeutic drug for primary malignant bone tumors, utilizing the proprietary oncolytic adenovirus "Surv.m-CRA-1," has been designated as an "Orphan Regenerative Medicine Product" by the Minister of Health, Labour and Welfare. This designation is expected to accelerate the development and practical application of the treatment, providing hope for patients with intractable diseases.
- Q: What is the direct answer?
- A: Serve BioPharma announced on May 8, 2026, that its therapeutic drug for primary malignant bone tumors, utilizing the proprietary oncolytic adenovirus "Surv.m-CRA-1," has been designated as an "Orphan Regenerative Medicine Product" by the Minister of Health, Labour and Welfare. This designation is expected to accelerate the development and practical application of the treatment, providing hope for patients with intractable diseases.
- Q: What is the source and date?
- A: Source: https://prtimes.jp/main/html/rd/p/000000012.000165403.html | Date: Tue May 12 2026 04:32:40 GMT+0900 (Japan Standard Time)